Repligen Corporation Stock Price and Value Analysis

Should you buy Repligen Corporation stock? (NasdaqGS:RGEN). Let's see how it does in our automated value investing analysis system.

  • This company is making money at a modest rate.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company is less known than others.
  • This company pays no dividend.

RGEN Free Cash Flow Trend

Based on historical returns, we believe that Repligen Corporation can grow its free cash at a rate of about 1%. That's positive!

Free Cash Flow trendline for Repligen Corporation

Inside the RGEN Numbers

RGEN Price
(Repligen Corporation stock price per share)
[?] RGEN Fair Price
(based on intrinsic value)
[?] RGEN Safety Price (based on a variable margin of safety) $8.09
[?] PE Ratio versus Sector 151% higher than other Healthcare stocks
[?] PE Ratio versus Industry 11% lower than other Biotechnology stocks
[?] Free Cash Flow Jitter 76%

Is Repligen Corporation Stock on Sale?

We believe that Repligen Corporation may be worth examining further. It's making money, which is a very positive sign. Is it on sale?

Repligen Corporation looks overpriced right now. If you're looking for a bargain in the stock market, you should probably look elsewhere for a great deal. This might still be a great stock to own—but it's not on sale right now.

Should You Buy RGEN Stock?

Does Repligen Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.